Literature DB >> 23994221

Does soluble fms-like tyrosine kinase-1 regulate placental invasion? Insight from the invasive placenta.

Kerry McMahon1, S Ananth Karumanchi2, Isaac E Stillman3, Peter Cummings1, Dorothy Patton1, Thomas Easterling1.   

Abstract

OBJECTIVE: Soluble fms-like tyrosine kinase (sFLT-1) is a potent antiangiogenic growth factor that has been found to be markedly elevated in preeclampsia. In healthy pregnancy, serum sFLT-1 concentrations are 50-fold higher than in the nonpregnant state. The functional significance of this physiologic elevation in serum sFLT-1 in normal pregnancy is unknown. We hypothesized that sFLT-1 regulates placental cytotrophoblast invasion and that lower levels of sFLT-1 would be observed locally in invasive placentas (accreta/increta/percreta). STUDY
DESIGN: We performed a retrospective case-control study comparing placental sFLT-1 expression in hysterectomy specimens from 3 groups: group 1, focally invasive placenta; group 2, normal invasion from the same specimen; and group 3, normal invasion associated with placenta previa. Immunohistochemistry for sFLT-1 was performed, and staining intensity was graded on a scale from 1+ (weak) to 5+ (strong).
RESULTS: We identified 10 hysterectomy specimens from women with invasive placentation and 3 with placenta previa. The median sFLT-1 staining score for group 1 was 1.75 compared to 4.0 for group 2 (P = .01). A significant difference was also found between group 1 and group 3 (P = .01). When comparing depth of invasion, there was a trend toward lower staining score as depth of invasion increased (P = .11). Interobserver agreement for immunohistochemistry scoring was 87%.
CONCLUSION: Lower levels of sFLT-1 protein expression were associated with invasive placentation suggesting a critical functional role for sFLT-1 in regulation of placental invasion.
Copyright © 2014 Mosby, Inc. All rights reserved.

Entities:  

Keywords:  placenta percreta; soluble fms-like tyrosine kinase; vascular endothelial growth factor

Mesh:

Substances:

Year:  2013        PMID: 23994221     DOI: 10.1016/j.ajog.2013.08.032

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  13 in total

1.  Apheresis to Treat Preeclampsia: Insights, Opportunities and Challenges.

Authors:  Thomas R Easterling
Journal:  J Am Soc Nephrol       Date:  2015-09-24       Impact factor: 10.121

2.  Angiogenic and immune signatures in plasma of young relatives at familial high-risk for psychosis and first-episode patients: A preliminary study.

Authors:  Paulo L Lizano; Matcheri S Keshavan; Neeraj Tandon; Ian T Mathew; Suraj Sarvode Mothi; Debra M Montrose; Jeffrey K Yao
Journal:  Schizophr Res       Date:  2015-12-11       Impact factor: 4.939

Review 3.  The role of decidual cells in uterine hemostasis, menstruation, inflammation, adverse pregnancy outcomes and abnormal uterine bleeding.

Authors:  Frederick Schatz; Ozlem Guzeloglu-Kayisli; Sefa Arlier; Umit A Kayisli; Charles J Lockwood
Journal:  Hum Reprod Update       Date:  2016-02-23       Impact factor: 15.610

4.  Spectrum of Factors Triggering Endothelial Dysfunction in PIH.

Authors:  Visala Sree Jammalamadaga; Philips Abraham
Journal:  J Clin Diagn Res       Date:  2016-12-01

5.  Interferon-α and angiogenic dysregulation in pregnant lupus patients who develop preeclampsia.

Authors:  Danieli Andrade; Mimi Kim; Luz P Blanco; S Ananth Karumanchi; Gloria C Koo; Patricia Redecha; Kyriakos Kirou; Angela M Alvarez; Melissa J Mulla; Mary K Crow; Vikki M Abrahams; Mariana J Kaplan; Jane E Salmon
Journal:  Arthritis Rheumatol       Date:  2015-04       Impact factor: 10.995

6.  Serum Angiogenic and Anti-angiogenic Markers in Pregnant Women with Placenta Percreta.

Authors:  Hacer Uyanıkoğlu; Adnan İncebıyık; Ahmet B Turp; Güler Çakmak; Sibel Sak; Neşe G Hilali
Journal:  Balkan Med J       Date:  2017-09-13       Impact factor: 2.021

Review 7.  Pathogenesis of Preeclampsia and Therapeutic Approaches Targeting the Placenta.

Authors:  Manoj Kumar Jena; Neeta Raj Sharma; Matthew Petitt; Devika Maulik; Nihar Ranjan Nayak
Journal:  Biomolecules       Date:  2020-06-24

Review 8.  Placenta Accreta Spectrum: A Review of Pathology, Molecular Biology, and Biomarkers.

Authors:  Helena C Bartels; James D Postle; Paul Downey; Donal J Brennan
Journal:  Dis Markers       Date:  2018-07-03       Impact factor: 3.434

9.  The expression and biological function of chemokine CXCL12 and receptor CXCR4/CXCR7 in placenta accreta spectrum disorders.

Authors:  Yu Long; Yonghua Jiang; Jingjing Zeng; Yiwu Dang; Yue Chen; Jueying Lin; Hongwei Wei; Hongwei Xia; Junqing Long; Cuizhen Luo; Zhiwei Chen; Yaling Huang; MuJun Li
Journal:  J Cell Mol Med       Date:  2020-01-28       Impact factor: 5.310

10.  Development and validation of a four-microRNA signature for placenta accreta spectrum: an integrated competing endogenous RNA network analysis.

Authors:  Tian Yang; Na Li; Rui Hou; Chong Qiao; Caixia Liu
Journal:  Ann Transl Med       Date:  2020-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.